Can be used for maintenance when compliance is a problem.
|
AMBER Flupentixol decanoate
|
| injection 20mg/ml, 1mL, 2mL |
| concentrate injection 100mg/ml, 0.5mL, 1mL |
AMBER Fluphenazine decanoate
|
| injection 25mg/ml, 0.5ml amp, |
| AMBER Haloperidol decanoate injection 100mg/mL |
| AMBER Pipotiazine palmitate injection 50mg/ml |
| AMBER Zuclopenthixol decanoate injection 200mg/ml, 500mg/ml |
| |
Risperdal Consta®
|
Risperdal Consta® restricted use – request from doctor must be sent to chief pharmacist and medical director of Lancashire Care Trust
|
before authorised to prescribe
|
RED Risperidone (Risperdal Consta®) injection
|
| 25mg, 37.5mg. 50mg |
| |
Abilify Maintena®, Xeplion®
|
Aripiprazole prolonged-release (PR) suspension for injection and Paliperidone palmitate (PR) suspension for injection are
|
recommended as treatment options in the maintenance treatment of schizophrenia in adult patients stabilised with oral
|
aripiprazole where both of the following criteria are met;
|
| |
| > where treatment is in line with the recommendations within NICE CG178 for the use of depot or long-acting injectable |
| antipsychotic medication and |
| > where treatment is in line with the Lancashire Care Guidance for Prescribing Second Generation Long Acting |
Antipsychotic Injections
|
| |
RED Aripiprazole (Abilify Maintena®) prolonged release suspension for injection, 400mg powder and solvent
|
RED *Paliperidone (Xeplion®) prolonged release suspension for injection, 50mg, 75mg,100mg,150mg
|
| |
| Paliperidone palmitate prolonged release suspension for injection (six monthly) |
| Paliperidone palmitate 6-monthly injection is recommended as a treatment option for the maintenance treatment of |
schizophrenia in adult patients who are clinically stable on 1-monthly or 3-monthly paliperidone palmitate injectable products:
|
| > where treatment is in line with the recommendations within NICE CG178 for the use of depot or long-acting injectable |
| antipsychotic medications, and |
| > where treatment is in line with the Lancashire Care Guidance for Prescribing Second Generation Long Acting Antipsychotic |
| injections |
| RED Paliperidone palmitate prolonged release suspension for injection (six monthly) (Byannli) |
| |
| |
*MHRA Drug Safety Alert - Risperidone and paliperidone: risk of intraoperative floppy iris syndrome in patients undergoing cataract surgery
|
All material in this section is aimed at health care professionals, but is information currently held in the public domain, members of the
public seeking advice on medicine-related matters are advised to speak with their GP, pharmacist, nurse or contact NHS111 Service
|
| Email: info.elmmb@nhs.net |
| |
| Copyright© 2016 East Lancashire Medicines Management Board. |
All rights reserved. Disclaimer/Terms and conditions
|
|
|
| |
| |
| |
| |
| |
| |
| |
| |
